CD8A and myeloid sarcoma: Since RUNX3 is a master regulator of both cytotoxicity [9] and TRM formation [10,11], it is tempting to speculate that RUNX3 together with EOMES and/or T-bet also determines the brain-homing potential of CD8+ memory T cells in MS patients.